Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
Ruby Gupta
, Sachin Gupta
, Bana Antonios
, Bipin Ghimire
, Vishal Jindal
, Jaskiran Deol
, Suzanna Gaikazian
, Marianne Huben
, Joseph Anderson
, Michael Stender
, Ishmael Jaiyesimi
Department of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
26
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Therapeutic landscape of advanced HER2-positive breast cancer in 2022'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Trastuzumab
100%
Therapeutic Landscapes
100%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
100%
Capecitabine
75%
Treatment Strategy
50%
Lapatinib
50%
Antibody-drug Conjugate
50%
HER2-targeted Therapy
50%
T-DM1
50%
Clinical Trials
25%
Clinical Outcomes
25%
Randomized Trial
25%
Rapidly Evolving
25%
5-year Survival
25%
Chemotherapy
25%
Advanced Stage
25%
Breast Cancer Patients
25%
Immune Cells
25%
Management Outcome
25%
Novel Agents
25%
Multiple Approaches
25%
FDA-approved Drugs
25%
Human Epidermal Growth Factor Receptor 2 (HER2)
25%
Breast Cancer Subtypes
25%
New Agents
25%
Tyrosine Kinase Inhibitor
25%
Third-line Treatment
25%
Second-line Treatment
25%
Metastatic Setting
25%
Pertuzumab
25%
Anti-HER2 Antibody
25%
Inhibitor Agent
25%
Aggressive Subtypes
25%
Cell Cycle Inhibitors
25%
Anti-HER2
25%
Third-line Therapy
25%
Taxane-based Chemotherapy
25%
Later-line Treatment
25%
Tucatinib
25%
Trastuzumab Emtansine
25%
Neratinib
25%
Treatment Lines
25%
Pharmacology, Toxicology and Pharmaceutical Science
Trastuzumab
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Capecitabine
75%
Chemotherapy Regimens
50%
Lapatinib
50%
Breast Cancer
25%
Clinical Trial
25%
Survival Rate
25%
Immunotherapy
25%
Monoclonal Antibody
25%
Mammalian Target of Rapamycin Inhibitor
25%
Protein Tyrosine Kinase Inhibitor
25%
Taxane
25%
Trastuzumab Emtansine
25%
Pertuzumab
25%
Tucatinib
25%
Neratinib
25%
Trastuzumab Deruxtecan
25%